Literature DB >> 16800744

Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells.

Panagiotis Prezas1, Matthias J E Arlt, Petar Viktorov, Antoninus Soosaipillai, Leon Holzscheiter, Manfred Schmitt, Maroulio Talieri, Eleftherios P Diamandis, Achim Krüger, Viktor Magdolen.   

Abstract

The human tissue kallikrein family of serine proteases (hK1-hK15 encoded by the genes KLK1-KLK15) is involved in several cancer-related processes. Accumulating evidence suggests that certain tissue kallikreins are part of an enzymatic cascade pathway that is activated in ovarian cancer and other malignant diseases. In the present study, OV-MZ-6 ovarian cancer cells were stably co-transfected with plasmids expressing hK4, hK5, hK6, and hK7. These cells displayed similar proliferative capacity as the vector-transfected control cells (which do not express any of the four tissue kallikreins), but showed significantly increased invasive behavior in an in vitro Matrigel invasion assay (p<0.01; Mann-Whitney U-test). For in vivo analysis, the cancer cells were inoculated into the peritoneum of nude mice. Simultaneous expression of hK4, hK5, hK6, and hK7 resulted in a remarkable 92% mean increase in tumor burden compared to the vector-control cell line. Five out of 14 mice in the 'tissue kallikrein overexpressing' group displayed a tumor/situs ratio greater than 0.198, while this weight limit was not exceeded at all in the vector control group consisting of 13 mice (p=0.017; chi2 test). Our results strongly support the view that tumor-associated overexpression of tissue kallikreins contributes to ovarian cancer progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16800744     DOI: 10.1515/BC.2006.102

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  29 in total

1.  Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome.

Authors:  Lakmali Munasinghage Silva; Thomas Kryza; Thomas Stoll; Christine Hoogland; Ying Dong; Carson Ryan Stephens; Marcus Lachlan Hastie; Viktor Magdolen; Oded Kleifeld; Jeffrey John Gorman; Judith Ann Clements
Journal:  Mol Cell Proteomics       Date:  2019-01-31       Impact factor: 5.911

2.  Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells.

Authors:  Rebecca S Henkhaus; Upal Kunal Basu Roy; Dora Cavallo-Medved; Bonnie F Sloane; Eugene W Gerner; Natalia A Ignatenko
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

3.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

4.  Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.

Authors:  Rebecca S Henkhaus; Eugene W Gerner; Natalia A Ignatenko
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

5.  Hypomaturation enamel defects in Klk4 knockout/LacZ knockin mice.

Authors:  James P Simmer; Yuanyuan Hu; Rangsiyakorn Lertlam; Yasuo Yamakoshi; Jan C-C Hu
Journal:  J Biol Chem       Date:  2009-05-06       Impact factor: 5.157

6.  Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7.

Authors:  Mekdes Debela; Petra Hess; Viktor Magdolen; Norman M Schechter; Thomas Steiner; Robert Huber; Wolfram Bode; Peter Goettig
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-01       Impact factor: 11.205

7.  Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma.

Authors:  Kristen L Drucker; Alex R Paulsen; Caterina Giannini; Paul A Decker; Sachiko I Blaber; Michael Blaber; Joon H Uhm; Brian P O'Neill; Robert B Jenkins; Isobel A Scarisbrick
Journal:  Neuro Oncol       Date:  2013-01-10       Impact factor: 12.300

8.  A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.

Authors:  Amiram Sananes; Itay Cohen; Anat Shahar; Alexandra Hockla; Elena De Vita; Aubry K Miller; Evette S Radisky; Niv Papo
Journal:  J Biol Chem       Date:  2018-06-22       Impact factor: 5.157

Review 9.  The biology of ovarian cancer: new opportunities for translation.

Authors:  Robert C Bast; Bryan Hennessy; Gordon B Mills
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

10.  The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer.

Authors:  M Talieri; L Li; Y Zheng; D K Alexopoulou; A Soosaipillai; A Scorilas; D Xynopoulos; E P Diamandis
Journal:  Br J Cancer       Date:  2009-04-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.